Safety of Hepatitis A Vaccine | Hepatitis Central

Hepatitis C, Safety and Immunogenicity of Hepatitis A Vaccine in Patients With Chronic Liver Disease

Safety and Immunogenicity of

Hepatitis A Vaccine in Patients With Chronic Liver Disease

Table 2. Adverse Events Related/Possibly Related to Vaccination with Hepatitis A and B Vaccines in Healthy Subjects and Persons With CLD

	Hepatitis A Vaccine				HAV vs. HBV Vaccine
	Hepatitis A Vaccine				Hepatitis C
	Healthy (n = 371)	Hepatitis B (n = 91)	Hepatitis C (n = 200)	Others^* (n = 136)	(n = 200)	(n = 197)

Local symptoms	37.2%	44%	37.5%	44.9%	37.5%	19.8%
		(P = .279)	(P = 1.000)	(P = .125)	(P = .0001)
General symptoms	11.1%	16.5%	24.5%	27.9%	24.5%	19.3%
		(P = .007)	(P < .0001)	(P < .0001)	(P = .207)

NOTE. The incidence of local and general symptoms in each of the cohorts of CLD subjects was compared separately with that in healthy subjects by Fisher’s Exact test. Abbreviation: HBV, hepatitis B virus. ^* Others = chronic liver disease of etiology other than hepatitis B or C.